Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
greater decrease » greater increase (Expand Search), greater disease (Expand Search), rate decreased (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
greater decrease » greater increase (Expand Search), greater disease (Expand Search), rate decreased (Expand Search)
-
2401
-
2402
Verification of PLUS CYCLE<sup>®</sup> signals during presumed sleep periods.
Published 2025Subjects: -
2403
-
2404
-
2405
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
2406
-
2407
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2408
-
2409
-
2410
-
2411
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2412
-
2413
-
2414
-
2415
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2416
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2417
-
2418
-
2419
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2420